Irfan Hassam-Malani
Associate
-
-
Phone: +1 312 499 6708
- Duane Morris LLP
190 South LaSalle Street, Suite 3700
Chicago, IL 60603-3433
USA
Irfan Hassam-Malani practices in the area of intellectual property law. Mr. Hassam-Malani has experience with counseling clients through patent preparation and prosecution, product clearance and litigation, working primarily with large global manufacturers in the consumer electronics, telecommunications, chemical and agricultural sciences industries. He has also managed extensive global patent portfolio and application strategy for a worldwide leader in aviation technology.
Mr. Hassam-Malani is a 2021 cum laude graduate of the University of Illinois at Urbana-Champaign College of Law, where he was notes editor of the Elder Law Journal, and a graduate of the University of Illinois at Urbana-Champaign (B.S., Chemistry; B.A.&Sc., Economics). He speaks English and Hindi.
Admissions
- Illinois
- U.S. Patent and Trademark Office (USPTO)
Education
- University of Illinois College of Law, J.D., cum laude, 2021
- Notes Editor, The Elder Law Journal - University of Illinois at Urbana-Champaign, B.S., Chemistry, 2018
- University of Illinois at Urbana-Champaign, B.A.&Sc., Economics, 2018
Experience
- Duane Morris LLP
- Associate, 2022-present - Fitch, Even, Tabin & Flannery LLP
- Associate, 2021-2022
Professional Activities
- Chicago Bar Association
- Member, 2021-present - South Asian Bar Association
- Member, 2021-present
Honors and Awards
- Recipient of CALI Award in Patent Research & Strategy
- ABA Client Counseling Competition Semi-Finalist
- Advanced Trial Team Quarterfinalist and Finalist
- Williams Institute Moot Court Competition Team
Selected Publications
- Co-author, "FDA Adopts ISO Standard for Device Makers in New Rule," Duane Morris Alert, March 18, 2024
- Co-author, "Customer-Suit Exception Extends to Joinder of Customers and Manufacturers in the Same Suit," Duane Morris Alert, February 10, 2023
- Co-author, "FDA and USPTO Announce Public Listening Session to Promote Greater Access to Medicines," Duane Morris Alert, December 27, 2022
- Co-author, "FDA Issues Guidance on the Background and Evaluation of Therapeutic Equivalence Codes," Duane Morris Alert, August 4, 2022
- Co-author, "FDA Issues Guidance on Compounding Animal Drugs from Bulk Drug Substances," Duane Morris Alert, April 20, 2022
Representative Matters
Represented Somerset Therapeutics LLC in settling Hatch-Waxman litigation related to 0.7% olopatadine ophthalmic solution in the United States, a generic version of PATADAY® Once-Daily, permitting entry into the market prior to patent expiry.